ReviewMolecular biomedicine2025
Multi-omics strategies for biomarker discovery and application in personalized oncology.
Review in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Blood-based biomarkers of protein digestibility, utilization, and nitrogen excretion in animals: Concepts, evidence, and applications.Veterinary and animal science · 2026Review
- Multi-omics integration of proteomics and metabolomics in pediatric health and disease.Communications medicine · 2026Review
- Insights into the Complexities of Pharmacotherapy Parameters in Artificial Intelligence Models for Drug Selection, Precision Personalised Medicine and Optimal Therapeutic Outcomes.Pharmaceutics · 2026Review
- Ferroptosis Signatures in Diabetic Cardiomyopathy: Multi-Omics Discovery and Validation of ACOT1 and TXNIP.Current issues in molecular biology · 2026Article
- The RNA-Binding Protein ELAVL4/HuD Promotes Stress-Associated Tumor Survival in Neuroendocrine Cancers.International journal of molecular sciences · 2026Review
- Article
- Enzyme-Metabolite Network Analysis of Endometrial Cancer-Derived Extracellular Vesicles Through Integrated Proteomics and Metabolomics.International journal of molecular sciences · 2026Article
- Multi-omics-driven precision medicine.iMeta · 2026Review
- Neurons Die Not by One Hit, but by Signaling Convergence.Molecular neurobiology · 2026Review
- Mapping the path to clinical implementation of multi-omics.Nature genetics · 2026Review
- Multi-Omics-Guided Design and Safety Engineering of Nucleic Acid Therapeutics: From Molecular Perturbation to Predictive Toxicology and Precision Translation.Chemical biology & drug design · 2026Review
- Proteomic Biomarker Discovery in Breast Cancer: Advances, Challenges, and Translational Prospects.Journal of biochemical and molecular toxicology · 2026Review
- Bridging In Vitro and Murine Breast Cancer Models: Advanced Imaging Across Multiscale Experimental Platforms.Cancers · 2026Review
- Multi-omic Profiling of Recurrence Risk Across Breast Cancer Subtypes.medRxiv : the preprint server for health sciences · 2026Article
- Data-intensive immune network modelling for One Health.Briefings in bioinformatics · 2026Review
- Multi-Omics Integration in Stroke: Neuroinflammatory Endotypes, Immune Cell Crosstalk, and Precision Biomarker Discovery.International journal of molecular sciences · 2026Review
- Metabolic enzymes and immune receptors as emerging checkpoints in breast cancer: mechanisms, clinical trials, and therapeutic implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review).Oncology reports · 2026Review
- VEGFC as a prognostic cytokine biomarker linking lymph node metastasis to immune suppression in breast cancer.European cytokine network · 2026Article
- TCM-Derived Small Molecules Targeting Metabolic Vulnerabilities in NSCLC: Ferroptosis-Centered Mechanisms and Emerging Cuproptosis- and Disulfidptosis-Related Vulnerabilities.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Multi-omics strategies, integrating genomics, transcriptomics, proteomics, and metabolomics, have revolutionized biomarker discovery and enabled novel applications in personalized oncology. Despite rapid technological developments, a comprehensive synthesis addressing integration strategies, analytical workflows, and translational applications has been lacking. This review presents a comprehensive framework of multi-omics integration, encompassing workflows, analytical techniques, and computational tools for both horizontal and vertical integration strategies, with particular emphasis on machine learning and deep learning approaches for data interpretation. Recent applications of multi-omics have yielded promising biomarker panels at the single-molecule, multi-molecule, and cross-omics levels, supporting cancer diagnosis, prognosis, and therapeutic decision-making. However, major challenges persist, particularly in data heterogeneity, reproducibility, and the clinical validation of biomarkers across diverse patient populations. This review also highlights cutting-edge advances in single-cell multi-omics and spatial multi-omics technologies, which are expanding the scope of biomarker discovery and deepening our understanding of tumor heterogeneity. Finally, we discuss the integral role of multi-omics in personalized oncology, with a particular focus on predicting drug responses and optimizing individualized treatment strategies, supported by real-world clinical practice cases. By bridging technological innovations with translational applications, this review aims to provide a valuable resource for researchers and clinicians, offering insights into both current methodologies and future directions for implementing multi-omics data in biomarker discovery and personalized cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.